Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia
Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia
Dr. Julia Maxson, Ph.D. – Oregon Health & Science University – OHSU, Portland, OR
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Dr. Abby Green, M.D. – Washington University, School of Medicine, St. Louis, MO
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dr. Palaniraja Thandapani, Ph.D. – University of Texas M.D. Anderson Cancer Center, Houston, TX
Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients
Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients
Dr. Kristopher Sarosiek, Ph.D. – President and Fellows of Harvard College, Harvard T. H. Chan School of Public Health, Boston, MA
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Dr. John Prensner, M.D., Ph.D. – University of Michigan Medical Center (Michigan Medicine), Ann Arbor, MI
Validating PRL2 as a New Therapeutic Target in T-ALL
Validating PRL2 as a New Therapeutic Target in T-ALL
Dr. Loretta Li, M.D. – Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
Dr. Liron Grossmann, M.D. – The Sheba Fund for Health Service and Research, Israel
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
Dr. William Carroll, M.D. – New York University Grossman School of Medicine, New York, NY